Pfizer, PhRMA See Signs Of Drug Approval "Slowdown" At FDA

Pfizer believes that several of its pending products have been delayed by an "across-the-board" slowdown in FDA approvals, CEO Henry McKinnell told investors during the company's Jan. 24 quarterly conference call.